2019
PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway
Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Cornud F, Haider M, Macura K, Tempany C, Verma S, Weinreb J. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology 2019, 292: 464-474. PMID: 31184561, PMCID: PMC6677282, DOI: 10.1148/radiol.2019182946.Peer-Reviewed Original ResearchConceptsBiopsy pathwayProstate cancerLife-threatening prostate cancerBiopsy-naive menNegative biopsy resultsClinical care guidelinesHigh-quality evidenceSignificant prostate cancerRoutine clinical practiceProstate Imaging ReportingGreater clinical utilityNumber of diagnosesProstate cancer detectionClinical suspicionInsignificant cancerCare guidelinesBiopsy resultsProstate biopsyTransrectal USMRI pathwayPositive health impactsNumber of menBiopsy increasesIncorporation of MRIClinical utility
2017
Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volume
2016
MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.Peer-Reviewed Original ResearchBiopsy-naive menMRI-US fusionGleason scoreProstate cancerMapping biopsyProstate biopsyCS prostate cancerPre-biopsy mpMRITemplate mapping biopsyLow-grade diseaseCancer detection rateMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreCS cancerPrevious biopsyPrior biopsyBiopsy resultsFusion biopsyInclusion criteriaMp-MRIPatient basisPatientsBiopsyCancerMRI-US fusion targeted biopsy results in men with a history of prior cancer.
Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.Peer-Reviewed Original ResearchMRI-US fusionGleason scoreActive surveillanceFusion biopsySignificant cancerProstate cancerGleason 6 prostate cancerPre-biopsy mpMRIPrevious prostate biopsyAppropriate risk stratificationMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreUpstaging rateC cancerPrior cancerPrior biopsyMapping biopsyRisk stratificationHigher PSABiopsy resultsProstate biopsyInclusion criteriaMp-MRIPatient basisMRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsy
2015
MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE
Kardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE. Journal Of Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.Peer-Reviewed Original ResearchSimplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.
Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.Peer-Reviewed Original ResearchCancer detection rateOverall cancer detection rateSignificant prostate cancerProstate cancerSystematic biopsyProstate biopsyFusion biopsyCommon solid organ malignancyEndorectal coilCores TRUS biopsyPrior negative biopsySolid organ malignanciesFusion prostate biopsyCochran-Armitage trend testCause of cancerMagnetic resonance imagingReal-time ultrasoundArmitage trend testAbnormal DRELesion stratificationElevated PSAOrgan malignanciesLesion gradingNegative biopsyTRUS biopsy